Compare Stocks: ALDX, PALI, IKT, and TTRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALDX Aldeyra Therapeutics	$1.56 +8.3%	$1.81	$1.07 ▼ $6.18	$86.87M	1.21	951,454 shs	829,953 shs
IKT Inhibikase Therapeutics	$2.41	$2.07	$1.33 ▼ $2.53	$336.28M	0.95	783,509 shs	227,865 shs
PALI Palisade Bio	$2.14 -0.5%	$1.95	$0.53 ▼ $2.86	$374.68M	1.52	2.00 million shs	1.61 million shs
TTRX Turn Therapeutics	$9.57 -2.9%	$8.03	$2.57 ▼ $26.50	$293.71M	N/A	75,802 shs	98,233 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALDX Aldeyra Therapeutics	+8.33%	+0.65%	-18.75%	-7.14%	-70.95%
IKT Inhibikase Therapeutics	0.00%	-2.43%	+16.99%	+39.31%	+240,999,900.00%
PALI Palisade Bio	-0.47%	+1.42%	+5.42%	+16.94%	+163.94%
TTRX Turn Therapeutics	-2.94%	-8.07%	-0.10%	+136.30%	+956,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALDX Aldeyra Therapeutics	$1.56 +8.3%	$1.81	$1.07 ▼ $6.18	$86.87M	1.21	951,454 shs	829,953 shs
IKT Inhibikase Therapeutics	$2.41	$2.07	$1.33 ▼ $2.53	$336.28M	0.95	783,509 shs	227,865 shs
PALI Palisade Bio	$2.14 -0.5%	$1.95	$0.53 ▼ $2.86	$374.68M	1.52	2.00 million shs	1.61 million shs
TTRX Turn Therapeutics	$9.57 -2.9%	$8.03	$2.57 ▼ $26.50	$293.71M	N/A	75,802 shs	98,233 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALDX Aldeyra Therapeutics	+8.33%	+0.65%	-18.75%	-7.14%	-70.95%
IKT Inhibikase Therapeutics	0.00%	-2.43%	+16.99%	+39.31%	+240,999,900.00%
PALI Palisade Bio	-0.47%	+1.42%	+5.42%	+16.94%	+163.94%
TTRX Turn Therapeutics	-2.94%	-8.07%	-0.10%	+136.30%	+956,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALDX Aldeyra Therapeutics	2.00	Hold	$5.50	252.56% Upside
IKT Inhibikase Therapeutics	3.00	Buy	$5.40	124.07% Upside
PALI Palisade Bio	3.00	Buy	$9.00	320.56% Upside
TTRX Turn Therapeutics	2.50	Moderate Buy	$8.00	-16.41% Downside

Current Analyst Ratings Breakdown

Latest ALDX, PALI, IKT, and TTRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/31/2026	IKT Inhibikase Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
7/23/2026	PALI Palisade Bio	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$8.00
7/21/2026	TTRX Turn Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
7/20/2026	TTRX Turn Therapeutics	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/17/2026	IKT Inhibikase Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/14/2026	PALI Palisade Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/13/2026	TTRX Turn Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (D-)
7/13/2026	IKT Inhibikase Therapeutics	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
6/30/2026	PALI Palisade Bio	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$7.00
6/30/2026	PALI Palisade Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$2.00
6/29/2026	PALI Palisade Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 8/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	$0.63 per share	N/A
IKT Inhibikase Therapeutics	$260K	1,293.43	N/A	N/A	$1.10 per share	2.19
PALI Palisade Bio	$250K	1,491.75	N/A	N/A	$0.70 per share	3.06
TTRX Turn Therapeutics	N/A	N/A	N/A	N/A	$0.02 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALDX Aldeyra Therapeutics	-$33.85M	-$0.39	N/A	N/A	N/A	N/A	-53.14%	-34.94%	N/A
IKT Inhibikase Therapeutics	-$48.26M	-$0.43	N/A	N/A	N/A	N/A	-42.80%	-40.58%	N/A
PALI Palisade Bio	-$16.78M	-$1.01	N/A	N/A	N/A	N/A	-33.47%	-31.79%	N/A
TTRX Turn Therapeutics	-$3.19M	-$0.29	N/A	N/A	N/A	N/A	-230.84%	-53.19%	N/A

Latest ALDX, PALI, IKT, and TTRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	IKT Inhibikase Therapeutics	-$0.09	-$0.11	-$0.02	-$0.11	N/A	N/A
8/10/2026	Q2 2026	PALI Palisade Bio	-$0.0522	-$0.05	+$0.0022	-$0.05	$0.50 million	$0.50 million
8/6/2026	Q2 2026	ALDX Aldeyra Therapeutics	-$0.0875	-$0.09	-$0.0025	-$0.09	$31.33 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	N/A
PALI Palisade Bio	N/A	N/A	N/A	N/A	N/A
TTRX Turn Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALDX Aldeyra Therapeutics	N/A	4.91	4.91
IKT Inhibikase Therapeutics	N/A	15.82	30.14
PALI Palisade Bio	N/A	24.26	23.71
TTRX Turn Therapeutics	8.83	1.19	2.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALDX Aldeyra Therapeutics	59.71%
IKT Inhibikase Therapeutics	3.81%
PALI Palisade Bio	11.79%
TTRX Turn Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ALDX Aldeyra Therapeutics	11.80%
IKT Inhibikase Therapeutics	7.10%
PALI Palisade Bio	0.07%
TTRX Turn Therapeutics	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALDX Aldeyra Therapeutics	10	60.33 million	53.21 million	Optionable
IKT Inhibikase Therapeutics	6	139.54 million	129.63 million	N/A
PALI Palisade Bio	10	174.27 million	174.15 million	Not Optionable
TTRX Turn Therapeutics	2	29.79 million	N/A	N/A

ALDX, PALI, IKT, and TTRX Headlines

Recent News About These Companies

Turn Therapeutics (NASDAQ:TTRX) Stock Price Down 6.5% - Time to Sell?

August 13 at 12:59 AM | marketbeat.com

Turn Therapeutics Inc. GAAP EPS of -$0.20

August 13 at 9:51 AM | seekingalpha.com

Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results

August 12 at 5:00 PM | businesswire.com

Turn Therapeutics Inc. Share Price (TTRX.US)

August 5, 2026 | lse.co.uk

Turn Therapeutics Inc.

August 2, 2026 | cnn.com

Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026

July 28, 2026 | businesswire.com

Zacks Research Upgrades Turn Therapeutics (NASDAQ:TTRX) to Hold

July 23, 2026 | marketbeat.com

LADENBURG THALM/SH SH Upgrades Turn Therapeutics (NASDAQ:TTRX) to Strong-Buy

July 21, 2026 | marketbeat.com

Turn Therapeutics (NASDAQ:TTRX) Upgraded by Wall Street Zen to "Hold" Rating

July 18, 2026 | marketbeat.com

Turn Therapeutics Inc. (TTRX)

July 11, 2026 | sg.finance.yahoo.com

Why Is Turn Therapeutics Stock Trading Higher Today?

July 7, 2026 | benzinga.com

Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis

July 7, 2026 | businesswire.com

Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis

July 6, 2026 | businesswire.com

Turn Therapeutics Stock Short Interest Report | NASDAQ:TTRX | Benzinga

July 3, 2026 | benzinga.com

Turn Therapeutics appoints veteran executive to board

July 3, 2026 | theglobeandmail.com

TTRX Turn Therapeutics Inc.

June 19, 2026 | seekingalpha.com

Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis

June 1, 2026 | businesswire.com

Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model

May 27, 2026 | businesswire.com

Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026

May 19, 2026 | businesswire.com

Turn Therapeutics Appoints Former FDA Chief to Lead GX-03

May 18, 2026 | tipranks.com

Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead

May 18, 2026 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALDX, PALI, IKT, and TTRX Company Descriptions

Aldeyra Therapeutics NASDAQ:ALDX

$1.56 +0.12 (+8.33%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$1.50 -0.06 (-3.53%)

As of 08/14/2026 07:50 PM Eastern

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

Inhibikase Therapeutics NASDAQ:IKT

$2.41 0.00 (0.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$2.42 +0.00 (+0.21%)

As of 08/14/2026 07:34 PM Eastern

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.

Palisade Bio NASDAQ:PALI

$2.14 -0.01 (-0.47%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$2.11 -0.03 (-1.40%)

As of 08/14/2026 07:37 PM Eastern

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.

Turn Therapeutics NASDAQ:TTRX

$9.57 -0.29 (-2.94%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$9.84 +0.27 (+2.77%)

As of 08/14/2026 07:34 PM Eastern

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events. Our proprietary platform has been validated across multiple FDA-cleared medical devices. Our primary development programs focus on dermatological diseases, including moderate to severe eczema and onychomycosis. Our company’s origin is rooted in the personal journey of our founder, who developed a topical ointment to heal his own chronic, treatment-resistant wounds using the PermaFusion platform he developed. His initial formulation, now known as Hexagen (“Hexagen”) suspends certain antimicrobial/anti-inflammatory compounds in petrolatum without known cytotoxicity, irritation or sensitization. This formula has received three FDA clearances and has been utilized extensively in humans, which we believe demonstrates both technical proof of concept and meaningful therapeutic effects. The formula also has been demonstrated to provide anti-inflammatory immunological signaling (IL 36, IL 31, IL 4 inhibition), in-vivo nail penetration with fungal pathogen elimination, and other potential therapeutic benefits. These products are not presently on the market, and we are not currently generating revenue from these devices, as we focus on drug development of our core technology. In addition to our dermatology and wound programs, we are exploring broader applications of our PermaFusion technology. In partnership with a leading global nonprofit organization, we are attempting to develop intranasal vaccines with sufficient thermostability to withstand distribution without deep-freeze. Our goal is to eliminate the need for frozen storage and, thus, enable deployment and delivery to low-resource settings that do not maintain suitable cold storage infrastructure required for administration of modern-day vaccines. Furthermore, if we are successful in this initial program, we believe there may be opportunities to develop additional vaccines in thermostable, intranasal form. By reducing cold-storage infrastructure requirements and therefore enabling standard shipping of such vaccines, we believe intranasal vaccines have the potential to enhance patient uptake by enabling immunization in a broader variety of settings including in clinic, hospital and home-health settings. We believe this initiative highlights our platform’s versatility and its potential to unlock new therapeutic categories beyond dermatology. We have also completed preclinical, in-vivo xenograft studies for herpes zoster ophthalmicus (shingles of the eye) and basal cell carcinoma. A mildly reformulated version of the Hexagen formula was employed for the ocular study and compared this reformulation with placebo as a topical ocular agent intended to reduce viral load of herpes zoster in an animal model. Results obtained showed an 85% reduction in viral load compared to placebo without adverse events. For the basal cell carcinoma xenograft study, the Hexagen formula was compared to both placebo and 5-Fluorouracil (standard of care topical chemotherapy) as a topical treatment intended to reduce basal cell tumor size. The Hexagen formula showed an approximate 29% comparative reduction in tumor size to the placebo and an approximate 20% comparative reduction in tumor size compared to 5-Fluorouracil. We believe these preclinical in-vivo studies suggest meaningful potential in these indications, which we may continue to explore at the conclusion of our lead drug programs. We believe such exploratory results further underscore the potential breadth of opportunity enabled by our platform. We were initially formed on January 6, 2015, as Global Health Solutions, LLC, a Delaware limited liability company. On October 12, 2018, Global Health Solutions, LLC converted to a Delaware corporation under the name Global Health Solutions, Inc., dba Turn Therapeutics. Immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, we intend to change our name to Turn Therapeutics Inc. Our principal executive offices are located in Westlake Village, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALDX, PALI, IKT, and TTRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALDX, PALI, IKT, and TTRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALDX, PALI, IKT, and TTRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALDX, PALI, IKT, and TTRX Company Descriptions

Aldeyra Therapeutics NASDAQ:ALDX

Inhibikase Therapeutics NASDAQ:IKT

Palisade Bio NASDAQ:PALI

Turn Therapeutics NASDAQ:TTRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALDX, PALI, IKT, and TTRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALDX, PALI, IKT, and TTRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALDX, PALI, IKT, and TTRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALDX, PALI, IKT, and TTRX Company Descriptions

Aldeyra Therapeutics NASDAQ:ALDX

Inhibikase Therapeutics NASDAQ:IKT

Palisade Bio NASDAQ:PALI

Turn Therapeutics NASDAQ:TTRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools